← Therapy pipeline
Investigational · Obesity development

MariTide

maridebart cafraglutide · AMG 133 · Amgen

GLP-1 agonism with GIP receptor antagonism and less-frequent dosing under study.

GLP-1GIP
Other study areas
Type 2 diabetesLiver disease (MASLD / MASH)Sleep apneaCardiovascular outcomesHeart failureWeight maintenance / switching
Selected program areas, not approvals. See the full profile for individual trials.
Obesity stagePhase 3Updated as of November 2026
SponsorAmgen
TargetsGLP-1 + GIP
RouteInjection
DevelopmentObesity-specific
01 / Evidence

Selected study results

MariTide Phase 2 · weight management without type 2 diabetesMean body-weight reductionBody weight decreased 16.2% · 52 weeks · Phase 2
Phase 2 · Injection · Peer-reviewed results

Mean body-weight reduction · 52 weeks

Study focus: Weight management without type 2 diabetes

Investigational regimen
16.2%
Placebo / comparator
2.5%

Adults with obesity or overweight without type 2 diabetes · Highest-dose monthly regimen vs placebo · Trial N=465 · Treatment-policy estimand; highest-dose group. This is the main result shown for this study.. Results & methods ↗ · Publication ↗

Additional results or analyses from this same study
  • Same cohort · efficacy estimandAt the same highest monthly dose, the efficacy-estimand estimate was 19.9% mean weight reduction versus 2.6% with placebo at 52 weeks.
  • Type 2 diabetes cohort · treatment-policy estimandIn the separate type 2 diabetes cohort of this same Phase 2 study, mean weight reduction was 12.3% versus 1.7% with placebo at the highest monthly dose at 52 weeks.
  • Part 2 · maintenance follow-upThe sponsor reported that most selected participants who had lost at least 15% in Part 1 maintained that loss during a further 52 weeks on lower monthly or quarterly regimens. This was an exploratory extension. Follow-up source ↗

One Phase 2 study (NCT05669599) included separate cohorts with and without type 2 diabetes; the two additional values below are within-study analyses, not separate trials.

Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.

Sponsor announcements

Findings awaiting numerical detail

Dedicated MariTide Phase 2 diabetes study

Numerical results not disclosed in the cited update · 24 weeks · Phase 2

Amgen announced reductions in HbA1c and body weight at 24 weeks.

The cited sponsor announcement does not disclose arm-level numerical values or estimand details. A numerical comparison cannot be shown. This dedicated diabetes study is separate from the published 52-week obesity study above.

Sponsor announcement ↗
02 / How it works

Mechanism at a glance

GLP-1GLP-1Receptor agonist
GIPGIPReceptor antagonist
GCGglucagon—
AMYamylin—
OTHOther targets—
Explore the hormone anatomy ↗
03 / Development

Obesity stage by formulation

InjectionMonthly; less-frequent schedules under study
Phase 3Initiated
Milestone → next

Latest: Amgen’s November 3, 2026 update reports completed enrollment in MARITIME-CV, both OSA studies and the Phase 2b liver-fat study; MARITIME-T2D-3 has initiated. These enrollment milestones are not study completion or new efficacy results.

Next: MARITIME obesity and related-condition outcomes. Two additional Phase 3 type 2 diabetes studies remain planned for Q4 2026.

04 / Study records

Clinical study records

Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.

Obesity and weight-management studies

Phase 3 studies6 records

Phase 3

MARITIME-1

Weight management without type 2 diabetes
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Chronic weight management in adults with obesity or overweight without type 2 diabetes; ongoing per Amgen Q2 2026 update.

Phase 3

MARITIME-1 EXTENSION

Weight-loss maintenance
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Long-term maintenance in eligible MARITIME-1 completers without type 2 diabetes; monthly, every-eight-week or quarterly regimens. Enrolling per Amgen’s November 3 update.

Phase 3

MARITIME-2

Weight management with type 2 diabetes
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Chronic weight management in adults with obesity or overweight with type 2 diabetes; ongoing per Amgen Q2 2026 update.

Phase 3

MARITIME-2 EXTENSION

Weight-loss maintenance with type 2 diabetes
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Long-term maintenance in eligible MARITIME-2 completers with type 2 diabetes; monthly or every-eight-week regimens. Enrolling per Amgen’s November 3 update.

Phase 3

MARITIME-SWITCH

Weight maintenance / switching
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Evaluates switching adults with overweight or obesity from weekly semaglutide or tirzepatide to MariTide; enrolling per Amgen November 3, 2026 update.

Phase 3 planned

Additional type 2 diabetes program

Weight management with type 2 diabetes
Study: PlannedResults: No results reported; study plannedStatus reviewed September 2026

Amgen said three Phase 3 MariTide studies in people with type 2 diabetes were planned to initiate in 2026; individual study registrations and current initiation status were not matched in this review.

Phase 2 studies1 record

Phase 2

Phase 2 obesity study

Weight management
Study: CompletedResults: Peer-reviewed results shown aboveStatus reviewed November 2026

One 52-week dose-ranging study with separate cohorts with and without type 2 diabetes; treatment-policy estimate is the main result, with the efficacy estimand shown as a within-study note.

Related conditions and outcomes

Phase 3 studies5 records

Phase 3

MARITIME-CV

Cardiovascular outcomes
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Cardiovascular outcomes in adults with established atherosclerotic cardiovascular disease and overweight or obesity. Amgen’s November 3, 2026 update reports enrollment complete; results remain pending.

Phase 3

MARITIME-HF

Heart-failure outcomes
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Mortality, morbidity, and symptoms in adults with HFpEF or HFmrEF and obesity; enrolling per Amgen November 3, 2026 update.

Phase 3

MARITIME-OSA-1

Sleep-apnea outcomes
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Obstructive sleep apnea in adults on positive airway pressure therapy with overweight or obesity. Amgen’s November 3, 2026 update reports enrollment complete; results remain pending.

Phase 3

MARITIME-OSA-2

Sleep-apnea outcomes
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Obstructive sleep apnea in adults not on positive airway pressure therapy with overweight or obesity. Amgen’s November 3, 2026 update reports enrollment complete; results remain pending.

Phase 3

MARITIME-T2D-3

Glycemic control in type 2 diabetes
Study: Initiated / enrolling per sponsor; registry not yet recruitingResults: No registry results posted yetStatus reviewed November 2026

Estimated 1,300 adults with type 2 diabetes; open-label monthly MariTide versus weekly semaglutide, primary HbA1c noninferiority at week 68. Sponsor reports initiation/enrollment November 3; the October 8 registry snapshot remains not yet recruiting.

Phase 2 studies2 records

Phase 2b

Elevated liver fat and weight-loss study

Liver outcomes (MASLD / MASH)
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Adults with elevated liver fat and overweight or obesity. Amgen’s November 3, 2026 update reports enrollment complete; results remain pending.

Phase 2

Phase 2 type 2 diabetes study

Glycemic control in type 2 diabetes
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Dedicated glycemic-control study in adults with type 2 diabetes, with and without obesity; 24-week findings were presented by Amgen in January 2026.